NYSE:MDT - Medtronic Stock Price, Price Target & More

Get Started

$84.64 -0.47 (-0.55 %)

(As of 05/21/2018 07:00 AM ET)

Previous Close$85.11

Today's Range$84.00 - $84.91

52-Week Range$76.41 - $89.72

Volume4.71 million shs

Average Volume5.28 million shs

Market Capitalization$114.72 billion

P/E Ratio18.05

Dividend Yield2.16%

Beta0.94

About Medtronic (NYSE:MDT)

Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment offers surgical care, wound closure, electrosurgical, hernia mechanical device, mesh implant, ablation, interventional lung, ventilator, capnography, airway, sensor, monitor, compression, dialysis, enteral feeding, wound care, and medical surgical products; stapling, vessel sealing, fixation, and hardware instruments; and gastrointestinal, temperature management, inhalation therapy, and renal care solutions. The company's Restorative Therapies Group segment offers products for spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis, as well as products to treat conditions of the ear, nose, and throat; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The company's Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and Web-based therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNYSE:MDT

CUSIP58505510

Webwww.medtronic.com

Phone353-1438-1700

Debt

Debt-to-Equity Ratio0.51

Current Ratio2.43

Quick Ratio2.09

Price-To-Earnings

Trailing P/E Ratio18.05

Forward P/E Ratio17.86

P/E Growth2.32

Sales & Book Value

Annual Sales$29.71 billion

Price / Sales3.86

Cash Flow$6.8093 per share

Price / Cash12.43

Book Value$36.83 per share

Price / Book2.30

Profitability

EPS (Most Recent Fiscal Year)$4.60

Net Income$4.03 billion

Net Margins9.44%

Return on Equity12.65%

Return on Assets6.58%

Miscellaneous

Employees91,000

Outstanding Shares1,355,370,000

Medtronic (NYSE:MDT) Frequently Asked Questions

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic declared a quarterly dividend on Friday, March 9th. Investors of record on Friday, March 23rd will be paid a dividend of $0.46 per share on Friday, April 13th. This represents a $1.84 annualized dividend and a yield of 2.17%. The ex-dividend date is Thursday, March 22nd. View Medtronic's Dividend History.

How will Medtronic's stock buyback program work?

Medtronic declared that its Board of Directors has initiated a stock buyback plan on Thursday, October 5th 2017, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 49% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's leadership believes its shares are undervalued.

How were Medtronic's earnings last quarter?

Medtronic PLC (NYSE:MDT) released its quarterly earnings data on Tuesday, February, 20th. The medical technology company reported $1.17 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.16 by $0.01. The medical technology company earned $7.37 billion during the quarter, compared to the consensus estimate of $7.20 billion. Medtronic had a return on equity of 12.65% and a net margin of 9.44%. The company's quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.12 earnings per share. View Medtronic's Earnings History.

When is Medtronic's next earnings date?

Medtronic is scheduled to release their next quarterly earnings announcement on Thursday, May, 24th 2018. View Earnings Estimates for Medtronic.

What price target have analysts set for MDT?

22 Wall Street analysts have issued 12-month target prices for Medtronic's stock. Their predictions range from $80.00 to $99.00. On average, they anticipate Medtronic's stock price to reach $91.3947 in the next year. View Analyst Ratings for Medtronic.

What are Wall Street analysts saying about Medtronic stock?

Here are some recent quotes from research analysts about Medtronic stock:

1. According to Zacks Investment Research, "Medtronic exited the fiscal second quarter on a mixed note. While the company demonstrated improved segmental performances at CER, escalating costs and expenses continue to weigh on the bottom line. Unfavorable currency translation also acted as a dampener. On the bright side, all major business groups contributed to solid top-line growth at CER, which highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. We are also encouraged by the solid growth trend in the United States as well as healthy global acceptance of its advanced therapies. The recent receipt of FDA approval and commercial launch of Azure pacemakers with BlueSync technology buoy optimism. Apart from product innovation, the company is focusing on geographical diversification of its businesses. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside." (11/23/2017)
2. Needham & Company LLC analysts commented, "On 11/8/17, MDT preannounced F2Q18 revenue of $7.050B (up 3% organic Y/Y) vs. consensus of $6.897M. The impact from Hurricane Maria was revised down to ~$60M from ~$250M, which equates to ~1% in quarterly revenue growth and ~$0.03 in non-GAAP EPS. MDT did not update its FY18 revenue or EPS guidance in the press release but did reaffirm F2Q18 non-GAAP EPS growth of flat to slightly up, excluding the ~$0.03 headwind. MDT is scheduled to report full F2Q18 results on 11/21/17 and we intend to wait until then to update our model." (11/9/2017)

Who are some of Medtronic's key competitors?

Some companies that are related to Medtronic include Varian Medical Systems (VAR), Sonova (SONVY), Masimo (MASI), LivaNova (LIVN), Getinge Group (GNGBY), CONMED (CNMD), NxStage (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT) and Fonar (FONR).

Who are Medtronic's key executives?

Medtronic's management team includes the folowing people:

Mr. Omar S. Ishrak, Chairman and Chief Exec. Officer (Age 62)
Ms. Karen L. Parkhill, Exec. VP & CFO (Age 53)
Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 56)
Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 57)
Mr. Mark Ploof, Sr. VP of Global Operations & Bus. Services

Has Medtronic been receiving favorable news coverage?

News headlines about MDT stock have trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medtronic earned a media sentiment score of 0.13 on Accern's scale. They also gave news articles about the medical technology company an impact score of 47.37 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Medtronic's major shareholders?

Medtronic's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.08%), Massachusetts Financial Services Co. MA (4.42%), Franklin Resources Inc. (2.65%), Artisan Partners Limited Partnership (1.66%), Northern Trust Corp (1.19%) and Barrow Hanley Mewhinney & Strauss LLC (1.12%). Company insiders that own Medtronic stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic.

Which institutional investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Asset Management One Co. Ltd., Point72 Asset Management L.P., Amundi Pioneer Asset Management Inc., OppenheimerFunds Inc., Swiss National Bank, Massachusetts Financial Services Co. MA and Barrow Hanley Mewhinney & Strauss LLC. Company insiders that have sold Medtronic company stock in the last year include Bryan C Hanson, Carol A Surface, Hooman Hakami, James T Lenehan, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic.

Which institutional investors are buying Medtronic stock?

MDT stock was acquired by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Westwood Holdings Group Inc., BlackRock Inc., Wells Fargo & Company MN, Artisan Partners Limited Partnership, OMERS ADMINISTRATION Corp, Neuberger Berman Group LLC and State of Tennessee Treasury Department. Company insiders that have bought Medtronic stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $84.64.

How big of a company is Medtronic?

Medtronic has a market capitalization of $114.72 billion and generates $29.71 billion in revenue each year. The medical technology company earns $4.03 billion in net income (profit) each year or $4.60 on an earnings per share basis. Medtronic employs 91,000 workers across the globe.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]

MarketBeat Community Rating for Medtronic (MDT)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		911 (Vote Outperform)
Underperform Votes:		583 (Vote Underperform)
Total Votes:		1,494

MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe MDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Medtronic (NYSE:MDT) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

22 Wall Street analysts have issued ratings and price targets for Medtronic in the last 12 months. Their average twelve-month price target is $91.3947, suggesting that the stock has a possible upside of 7.98%. The high price target for MDT is $99.00 and the low price target for MDT is $80.00. There are currently 5 hold ratings and 17 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.77	2.73	2.65	2.57
Ratings Breakdown:	0 Sell Rating(s) 5 Hold Rating(s) 17 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 15 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 10 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$91.3947	$91.2368	$91.0789	$88.35
Price Target Upside:	7.98% upside	16.28% upside	11.44% upside	7.30% upside

Medtronic (NYSE:MDT) Consensus Price Target History

Price Target History for Medtronic (NYSE:MDT)

Medtronic (NYSE:MDT) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/27/2018	Piper Jaffray Companies	Initiated Coverage	Overweight	$90.00	Medium
3/29/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$95.00 ➝ $90.00	Medium
3/20/2018	Oppenheimer	Reiterated Rating	Buy		Low
2/22/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $93.00	Low
2/14/2018	Royal Bank of Canada	Reiterated Rating	Outperform	$92.00	Medium
1/3/2018	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$92.50	High
1/2/2018	Bank of America	Upgrade	Neutral ➝ Buy		High
12/12/2017	Argus	Upgrade	Hold ➝ Buy	$81.27 ➝ $95.00	Low
12/12/2017	BMO Capital Markets	Boost Price Target	Outperform	$94.00	Low
11/23/2017	Jefferies Group	Reiterated Rating	Buy	$99.00	N/A
11/22/2017	Northland Securities	Reiterated Rating	Hold	$80.00	N/A
11/22/2017	Stifel Nicolaus	Boost Price Target	Hold	$83.00 ➝ $85.00	N/A
11/19/2017	SunTrust Banks	Set Price Target	Buy	$92.00	N/A
11/9/2017	Needham & Company LLC	Reiterated Rating	Buy	$94.00	N/A
11/3/2017	Cowen	Reiterated Rating	Buy	$95.00	N/A
10/9/2017	Leerink Swann	Reiterated Rating	Market Perform	$88.00 ➝ $85.00	N/A
10/9/2017	Wells Fargo	Downgrade	Outperform ➝ Market Perform	$93.00 ➝ $83.00	N/A
8/24/2017	UBS	Reiterated Rating	Overweight		Low
8/23/2017	Barclays	Lower Price Target	Overweight	$94.00 ➝ $92.00	Low
7/31/2017	Deutsche Bank	Set Price Target	Buy	$96.00	Low
7/6/2017	William Blair	Reiterated Rating	Outperform		Medium
5/26/2017	CIBC	Reiterated Rating	Buy		Low
5/16/2017	Goldman Sachs	Initiated Coverage	Neutral ➝ Neutral	$87.00	Low
3/20/2017	BTIG Research	Reiterated Rating	Neutral		Low
2/22/2017	Wedbush	Reiterated Rating	Neutral	$85.00	N/A
1/3/2017	JPMorgan Chase	Downgrade	Overweight ➝ Neutral	$84.00 ➝ $79.00	N/A
8/25/2016	Credit Suisse Group	Reiterated Rating	Outperform	$92.00	N/A
6/8/2016	Guggenheim	Initiated Coverage	Neutral		N/A

(Data available from 5/21/2016 forward)

Medtronic (NYSE:MDT) Earnings History and Estimates Chart

Earnings by Quarter for Medtronic (NYSE:MDT)

Medtronic (NYSE:MDT) Earnings Estimates

2018 EPS Consensus Estimate: $4.71
2019 EPS Consensus Estimate: $5.20

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	6	$1.07	$1.15	$1.10
Q2 2018	7	$0.89	$1.20	$1.03
Q3 2018	7	$1.15	$1.24	$1.18
Q4 2018	7	$1.38	$1.46	$1.40
Q1 2019	4	$1.12	$1.22	$1.18
Q2 2019	4	$1.18	$1.26	$1.21
Q3 2019	4	$1.29	$1.32	$1.30
Q4 2019	4	$1.46	$1.56	$1.51

Medtronic (NYSE MDT) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/24/2018		$1.40					N/A
2/20/2018	Q3 18	$1.16	$1.17	$7.2012 billion	$7.3690 billion	View	Listen
11/21/2017	Q2 18	$0.99	$1.07	$7.0493 billion	$7.05 billion	View	N/A
8/22/2017	7/31/2017	$1.08	$1.12	$7.4441 billion	$7.39 billion	View	N/A
5/25/2017	Q4 17	$1.31	$1.33	$7.8602 billion	$7.9160 billion	View	N/A
2/21/2017	1/31/2017	$1.11	$1.12	$7.2171 billion	$7.2830 billion	View	Listen
11/22/2016	Q217	$1.11	$1.12	$7.46 billion	$7.35 billion	View	Listen
8/25/2016	Q117	$1.01	$1.03	$7.1694 billion	$7.20 billion	View	Listen
5/31/2016	Q416	$1.26	$1.27	$7.49 billion	$7.57 billion	View	Listen
3/1/2016	Q316	$1.06	$1.06	$6.99 billion	$6.93 billion	View	Listen
12/3/2015	Q216	$1.00	$1.03	$7.0754 billion	$7.0580 billion	View	Listen
9/3/2015	Q116	$1.01	$1.02	$7.0291 billion	$7.2740 billion	View	Listen
6/2/2015	Q415	$1.11	$1.16	$7.1771 billion	$7.30 billion	View	Listen
2/17/2015	Q3	$0.97	$1.01	$4.25 million	$4.32 million	View	Listen
11/18/2014	Q2	$0.96	$0.96	$4.37 million	$4.40 million	View	Listen
8/19/2014	Q115	$0.92	$0.93	$4.25 billion	$4.27 billion	View	Listen
5/20/2014	Q414	$1.12	$1.12	$4.58 billion	$4.60 billion	View	Listen
2/18/2014	Q314	$0.91	$0.91	$4.15 billion	$4.20 billion	View	Listen
11/19/2013	Q214	$0.90	$0.91	$4.18 billion	$4.20 billion	View	Listen
8/20/2013	Q1 2014	$0.88	$0.88	$4.11 billion	$4.10 billion	View	Listen
5/21/2013	Q4 2013	$1.03	$1.10	$4.39 billion	$4.50 billion	View	Listen
2/19/2013	Q3 2013	$0.91	$0.93	$4.03 billion	$4.03 billion	View	Listen
11/20/2012	0.88		$0.88		$4.10 billion	View	N/A
8/21/2012		$0.85	$0.85			View	N/A
5/22/2012		$0.98	$0.99			View	N/A
2/21/2012		$0.84	$0.88			View	N/A
11/22/2011		$0.82	$0.84			View	N/A
8/23/2011		$0.79	$0.79			View	N/A
5/24/2011		$0.93	$0.90			View	N/A
2/22/2011		$0.84	$0.86			View	N/A
11/23/2010	Q2 2011	$0.81	$0.82			View	N/A
8/24/2010	Q1 2011	$0.82	$0.80			View	N/A
5/25/2010	Q4 2010	$0.88	$0.89			View	N/A
2/23/2010	Q3 2010	$0.76	$0.77			View	N/A
11/24/2009	Q2 2010	$0.74	$0.77			View	N/A
8/25/2009	Q1 2010	$0.78	$0.79			View	N/A
5/19/2009	Q4 2009	$0.82	$0.82			View	N/A
2/17/2009	Q3 2009	$0.71	$0.71			View	N/A
11/18/2008	Q2 2009	$0.71	$0.67			View	N/A
8/19/2008	Q1 2009	$0.69	$0.72			View	N/A
5/20/2008	Q4 2008	$0.73	$0.78			View	N/A
2/19/2008	Q3 2008	$0.61	$0.63			View	N/A

(Earnings results data provided by Zacks Investment Research)

Medtronic (NYSE:MDT) Dividend Information

Medtronic pays an annual dividend of $1.84 per share, with a dividend yield of 2.17%. MDT's most recent quarterly dividend payment was Friday, April 13. The company has grown its dividend for the last 40 consecutive years and is increasing its dividend by an average of 15.00% each year. Medtronic pays out 40.00% of its earnings out as a dividend.

Most Recent Dividend:	4/13/2018
Annual Dividend:	$1.84
Dividend Yield:	2.17%
Dividend Growth:	15.00% (3 Year Average)
Payout Ratio(s):	40.00% (Trailing 12 Months of Earnings) 38.82% (Based on This Year's Estimates) 35.80% (Based on Next Year's Estimates) 27.02% (Based on Cash Flow)
Track Record:	40 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Medtronic (NYSE:MDT)

Medtronic (NYSE:MDT) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/9/2018	Quarterly	$0.46	2.2%	3/22/2018	3/23/2018	4/13/2018
12/8/2017	Quarterly	$0.46		12/28/2017	12/29/2017	1/19/2018
8/28/2017	Quarterly	$0.46	2.31%	9/28/2017	9/29/2017	10/20/2017
6/23/2017	Quarterly	$0.46	2.07%	7/5/2017	7/7/2017	7/26/2017
3/10/2017	Quarterly	$0.43	2.08%	3/22/2017	3/24/2017	4/13/2017
12/9/2016	quarterly	$0.43	2.33%	12/21/2016	12/23/2016	1/13/2017
8/22/2016	Quarterly	$0.43	1.98%	9/27/2016	9/29/2016	10/21/2016
6/24/2016	quarterly	$0.43	1.85%	7/6/2016	7/8/2016	7/27/2016
2/22/2016	quarterly	$0.38	1.98%	3/22/2016	3/24/2016	4/15/2016
12/11/2015	quarterly	$0.38	1.96%	12/22/2015	12/24/2015	1/15/2016
8/21/2015	quarterly	$0.38	2.18%	9/23/2015	9/25/2015	10/16/2015
6/19/2015	quarterly	$0.38	1.97%	6/25/2015	6/29/2015	7/17/2015
2/20/2015	quarterly	$0.3050	1.55%	3/26/2015	3/30/2015	4/17/2015
12/4/2014		$0.3050		12/30/2014	1/2/2015	1/16/2015
12/5/2014	quarterly	$0.3050	1.63%	12/30/2014	1/2/2015	1/6/2015
8/21/2014	quarterly	$0.3050	1.92%	10/1/2014	10/3/2014	10/24/2014
6/16/2014	quarterly	$0.3050	1.98%	7/1/2014	7/3/2014	7/25/2014
2/14/2014	quarterly	$0.28	1.97%	4/2/2014	4/4/2014	4/25/2014
12/5/2013	quarterly	$0.28	1.93%	12/31/2013	1/3/2014	1/24/2014
8/22/2013	quarterly	$0.28	2.12%	10/2/2013	10/4/2013	10/25/2013
6/21/2013	quarterly	$0.28	2.13%	7/2/2013	7/5/2013	7/26/2013
2/15/2013	quarterly	$0.26	2.21%	4/3/2013	4/5/2013	4/26/2013
12/9/2012	quarterly	$0.26	2.44%	12/13/2012	12/17/2012	12/28/2012

(Data available from 1/1/2013 forward)

Medtronic (NYSE MDT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.31%
Institutional Ownership Percentage: 80.37%

Insider Trading History for Medtronic (NYSE:MDT)

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Medtronic (NYSE MDT) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2018	James T. Lenehan	Director	Sell	1,306	$83.56	$109,129.36
3/5/2018	Carol A Surface	SVP	Sell	24,479	$78.18	$1,913,768.22
1/9/2018	Richard Kuntz	VP	Sell	78,526	$86.21	$6,769,726.46	149,761
1/5/2018	Hooman Hakami	EVP	Sell	26,158	$85.00	$2,223,430.00
12/15/2017	Bryan C Hanson	EVP	Sell	16,000	$82.82	$1,325,120.00	88,818
11/16/2017	Bryan C. Hanson	EVP	Sell	16,000	$79.02	$1,264,320.00
10/16/2017	Bryan C Hanson	EVP	Sell	16,000	$78.03	$1,248,480.00
9/15/2017	Omar Ishrak	CEO	Sell	140,407	$81.63	$11,461,423.41	668,503
7/17/2017	Bryan C. Hanson	EVP	Sell	12,000	$88.57	$1,062,840.00
6/21/2017	Richard H Anderson	Director	Buy	5,600	$88.90	$497,840.00	71,910
3/20/2017	Hoedt Rob Ten	EVP	Sell	50,757	$81.58	$4,140,756.06	59,392
3/15/2017	Omar Ishrak	CEO	Sell	95,000	$82.82	$7,867,900.00	645,616
3/2/2017	Hooman Hakami	EVP	Sell	52,316	$82.33	$4,307,176.28	73,800
12/13/2016	Robert C. Pozen	Director	Buy	13,660	$73.21	$1,000,048.60
11/23/2016	James T. Lenehan	Director	Buy	2,000	$73.27	$146,540.00
9/27/2016	Richard Kuntz	VP	Sell	17,141	$86.70	$1,486,124.70	149,425
9/26/2016	Richard Kuntz	VP	Sell	25,199	$86.67	$2,183,997.33	149,425
9/15/2016	Kendall J. Powell	Director	Sell	7,907	$85.45	$675,653.15
9/15/2016	Omar Ishrak	CEO	Sell	61,925	$84.93	$5,259,290.25	565,916
8/29/2016	Bryan C Hanson	EVP	Sell	15,000	$87.00	$1,305,000.00	168,192
7/26/2016	Bryan C Hanson	EVP	Sell	15,000	$87.00	$1,305,000.00	108,717
7/15/2016	Geoffrey Martha	EVP	Sell	3,766	$88.26	$332,387.16
7/13/2016	Gary Lee Ellis	EVP	Sell	35,495	$88.64	$3,146,276.80
7/13/2016	Shirley A Jackson	Director	Sell	2,104	$88.64	$186,498.56	34,503
7/6/2016	Carol A. Surface	SVP	Sell	9,787	$87.08	$852,251.96
7/5/2016	Bryan C. Hanson	EVP	Sell	15,272	$87.11	$1,330,343.92
6/3/2016	Richard Kuntz	VP	Sell	49,905	$82.60	$4,122,153.00	127,647
4/1/2016	Richard Kuntz	VP	Sell	4,000	$75.22	$300,880.00	104,358
3/18/2016	Shirley A Jackson	Director	Sell	1,238	$75.60	$93,592.80	29,812
3/17/2016	Omar Ishrak	CEO	Sell	23,799	$76.15	$1,812,293.85	601,838
3/4/2016	Bryan C Hanson	EVP	Sell	5,000	$75.00	$375,000.00	96,806
2/5/2016	Bryan C. Hanson	EVP	Sell	5,000	$76.14	$380,700.00
1/8/2016	Bryan C Hanson	EVP	Sell	5,000	$75.00	$375,000.00	106,514
12/4/2015	Richard Kuntz	VP	Sell	13,715	$78.06	$1,070,592.90	108,086
9/15/2015	Omar Ishrak	CEO	Sell	20,000	$69.43	$1,388,600.00	526,824
7/14/2015	Carol A Surface	SVP	Sell	13,722	$75.83	$1,040,539.26
4/6/2015	Richard Kuntz	VP	Sell	31,768	$77.39	$2,458,525.52
3/25/2015	Gary Lee Ellis	CFO	Sell	43,183	$77.81	$3,360,069.23
3/13/2015	Omar Ishrak	CEO	Sell	20,000	$76.24	$1,524,800.00
2/19/2015	Christopher J Oconnell	EVP	Sell	50,361	$78.22	$3,939,237.42
12/19/2014	Richard Kuntz	VP	Sell	12,855	$74.54	$958,211.70
12/2/2014	Shirley A Jackson	Director	Sell	1,102	$74.43	$82,021.86
11/28/2014	Christopher J Oconnell	EVP	Sell	42,921	$73.95	$3,174,007.95
10/6/2014	Christopher J Oconnell	EVP	Sell	15,388	$64.98	$999,912.24
8/26/2014	Christopher J Oconnell	EVP	Sell	28,000	$63.57	$1,779,960.00
8/26/2014	Shirley A Jackson	Director	Sell	2,769	$63.66	$176,274.54
4/17/2014	Catherine Szyman	VP	Sell	29,420	$58.79	$1,729,601.80	21,602
4/9/2014	Richard Kuntz	VP	Sell	2,512	$60.98	$153,181.76	104,736
4/1/2014	Gary Lee Ellis	CFO	Sell	4,246	$61.48	$261,044.08	174,955
3/28/2014	Christopher Oconnell	EVP	Sell	1,982	$60.39	$119,692.98	120,652
3/20/2014	Catherine Szyman	VP	Sell	14,979	$59.57	$892,299.03	21,542
3/14/2014	Omar Ishrak	CEO	Sell	10,000	$59.12	$591,200.00	607,192
3/10/2014	Neil Ayotte	VP	Sell	1,845	$59.64	$110,035.80	10,782
12/4/2013	Neil Ayotte	VP	Sell	1,729	$57.14	$98,795.06	10,850
9/13/2013	Omar Ishrak	CEO	Sell	10,000	$53.58	$535,800.00	611,713
8/26/2013	Catherine Szyman	VP	Sell	56,998	$52.60	$2,998,094.80	21,217
8/22/2013	H James Dallas	VP	Sell	32,332	$53.19	$1,719,739.08	59,141
8/21/2013	H James Dallas	VP	Sell	36,256	$52.82	$1,915,041.92	91,473
8/21/2013	Shirley Jackson	Director	Sell	8,033	$52.84	$424,463.72	24,943
7/11/2013	Christopher J Oconnell	EVP	Sell	30,429	$52.92	$1,610,302.68
7/11/2013	Gary Lee Ellis	CFO	Sell	32,602	$53.62	$1,748,119.24
7/11/2013	H James Dallas	VP	Sell	69,889	$53.72	$3,754,437.08
7/1/2013	H James Dallas	VP	Sell	20,579	$52.10	$1,072,165.90
6/26/2013	D Cameron Findlay	VP	Sell	75,042	$52.20	$3,917,192.40
6/19/2013	H James Dallas	VP	Sell	94,117	$52.74	$4,963,730.58
5/22/2013	Richard H Anderson	Director	Buy	4,800	$52.32	$251,136.00
5/10/2013	Jack W Schuler	Director	Sell	34,230	$48.24	$1,651,255.20

(Data available from 1/1/2013 forward)

Medtronic (NYSE MDT) News Headlines

Source:

Date	Headline
	Analysts Anticipate Medtronic PLC (MDT) Will Post Quarterly Sales of $7.99 Billion www.americanbankingnews.com - May 21 at 4:57 AM
	Medtronic PLC (MDT) Expected to Post Earnings of $1.38 Per Share www.americanbankingnews.com - May 19 at 3:20 AM
	Medtronic Announces 2018 Institutional Investor and Analyst Meeting and Webcast finance.yahoo.com - May 18 at 5:25 PM
	Will Medtronic (MDT) Q4 Earnings Show Growth in All Lines? www.zacks.com - May 18 at 9:37 AM
	Medtronic (MDT) to Release Quarterly Earnings on Thursday www.americanbankingnews.com - May 17 at 1:16 AM
	Medtronic (MDT) Launches US Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients ... www.streetinsider.com - May 16 at 5:30 PM
	Medtronic Begins US Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with ... globenewswire.com - May 16 at 5:30 PM
	BRIEF-Medtronic Begins US Study To Evaluate Treatment Of Bifurcation Lesions In Patients With Coronary Artery ... www.reuters.com - May 16 at 5:30 PM
	Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease finance.yahoo.com - May 16 at 5:30 PM
	Detailed Research: Economic Perspectives on Medtronic, NVIDIA, NutriSystem, AmTrust Financial Services, Kratos ... globenewswire.com - May 16 at 8:59 AM
	Detailed Research: Economic Perspectives on Medtronic, NVIDIA, NutriSystem, AmTrust Financial Services, Kratos Defense & Security Solutions, and Envision Healthcare — What Drives Growth in Today's Competitive Landscape finance.yahoo.com - May 16 at 8:59 AM
	Mazor Robotics Starts Its "Transition" Year Strong www.fool.com - May 15 at 5:23 PM
	Medtronic (MDT) Highlights New Analysis Showing Cardiac Resynchronization Therapy Feature Associated with ... www.streetinsider.com - May 15 at 5:23 PM
	Mazor Robotics Starts Its "Transition" Year Strong finance.yahoo.com - May 15 at 5:23 PM
	Estimating The Intrinsic Value Of Medtronic plc (NYSE:MDT) finance.yahoo.com - May 15 at 8:25 AM
	New Study Demonstrates Feasibility of Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System to ... globenewswire.com - May 11 at 5:42 PM
	New Study Demonstrates Feasibility of Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System to Detect Atrial Contractions and Restore AV Synchrony finance.yahoo.com - May 11 at 5:42 PM
	Medtronic Study Confirms Feasibility of New Extravascular Approach to ICD Therapy finance.yahoo.com - May 11 at 5:42 PM
	Medtronic (MDT) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - May 10 at 5:45 PM
	Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2018 finance.yahoo.com - May 10 at 5:22 PM
	Here's How Medtronic Can Unlock Shareholder Value, Says Analyst www.thestreet.com - May 9 at 8:31 AM
	A Look at Abbott Laboratories’ Valuation Multiples finance.yahoo.com - May 8 at 8:33 AM
	Today’s Research Reports on Stocks to Watch: Tetraphase Pharmaceuticals and Medtronic finance.yahoo.com - May 8 at 8:33 AM
	Medtronic Hires JPMorgan Analyst, and Investors Rate It a 'Buy' www.bloomberg.com - May 7 at 5:24 PM
	Mike Weinstein to Join Medtronic as Senior Vice President of Strategy finance.yahoo.com - May 7 at 9:26 AM
	BRIEF-Lifetech Scientific Corp Receives Notice From Medtronic Group That Medtronic Entered Deal finance.yahoo.com - May 6 at 5:44 PM
	Medtronic (MDT) Expected to Announce Quarterly Sales of $7.98 Billion www.americanbankingnews.com - May 3 at 2:48 AM
	Medtronic Announces Advanced SynergyTLIF(SM) Workflow for Minimally Invasive Lumbar Spine Surgery finance.yahoo.com - May 2 at 5:21 PM
	Medtronic Announces FDA Approval of Infuse(TM) Bone Graft in New Spine Surgery Indications Using PEEK Interbody ... globenewswire.com - May 2 at 8:16 AM
	Reviewing Medtronic (MDT) & The Competition www.americanbankingnews.com - May 2 at 1:08 AM
	BRIEF-Medtronic Announces New Paid Family Care Leave Benefits www.reuters.com - May 1 at 5:21 PM
	BRIEF-Medtronic Receives FDA Approval For Deep Brain Stimulation Therapy For Type Of Epilepsy www.reuters.com - May 1 at 5:21 PM
	The Medical Record: Medtronic improves, Campbell expands, Methodist upgrades www.bizjournals.com - May 1 at 5:21 PM
	Medtronic Announces TiONIC(TM) Technology, a Titanium 3D Printed Platform for Spine Surgery Implants finance.yahoo.com - May 1 at 5:21 PM
	Medtronic Announces New Paid Family Care Leave Benefits finance.yahoo.com - May 1 at 5:21 PM
	$1.38 Earnings Per Share Expected for Medtronic (MDT) This Quarter www.americanbankingnews.com - May 1 at 3:10 PM
$Medtronic Receives FDA Approval for Deep Brain Stimulation Therapy for Medically Refractory Epilepsy$	Medtronic Receives FDA Approval for Deep Brain Stimulation Therapy for Medically Refractory Epilepsy finance.yahoo.com - May 1 at 8:07 AM
	Medtronic (MDT) & The Competition Critical Analysis www.americanbankingnews.com - May 1 at 5:08 AM
	BRIEF-Medtronic Announces FDA Approval Of Infuse Bone Graft In New Spine Surgery Indications www.reuters.com - April 30 at 5:25 PM
	Medtronic Announces FDA Approval of Infuse(TM) Bone Graft in New Spine Surgery Indications Using PEEK Interbody Implants finance.yahoo.com - April 30 at 5:25 PM
	Medtronic (MDT) and Its Competitors Critical Survey www.americanbankingnews.com - April 30 at 5:20 PM
	Critical Comparison: Medtronic (MDT) vs. Its Rivals www.americanbankingnews.com - April 30 at 1:22 PM
	Medtronic (MDT) vs. Its Rivals Critical Contrast www.americanbankingnews.com - April 29 at 9:12 PM
	Is Medtronic a Buy? 1 Analyst Thinks So www.fool.com - April 27 at 1:42 PM
	Piper Jaffray Initiates Coverage on Medtronic (MDT) www.americanbankingnews.com - April 27 at 12:13 PM
	Piper Jaffray Assumes Medtronic, Inc. (MDT) at Overweight www.streetinsider.com - April 27 at 8:27 AM
	Technical Perspectives on Medical Equipment Stocks -- LivaNova, Masimo, Medtronic, and MiMedx www.prnewswire.com - April 27 at 8:27 AM
	Two-Year Feasibility Study Results Encouraging with Medtronic Harmony(TM) Transcatheter Pulmonary Valve finance.yahoo.com - April 26 at 5:19 PM
	This Stock Play Is Finding Healthy Support In A Volatile Market finance.yahoo.com - April 26 at 8:26 AM
	Analyzing Medtronic (MDT) and Its Peers www.americanbankingnews.com - April 25 at 3:06 AM

Medtronic (NYSE:MDT) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Medtronic (NYSE:MDT) Income Statement, Balance Sheet and Cash Flow Statement

Medtronic (NYSE MDT) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff